Conserved allosteric inhibition mechanism in SLC1 transporters

  1. Yang Dong
  2. Jiali Wang
  3. Rachel-Ann Garibsingh
  4. Keino Hutchinson
  5. Yueyue Shi
  6. Gilad Eisenberg
  7. Xiaozhen Yu
  8. Avner Schlessinger  Is a corresponding author
  9. Christof Grewer  Is a corresponding author
  1. Binghamton University, United States
  2. Icahn School of Medicine at Mount Sinai, United States

Abstract

Excitatory Amino Acid Transporter 1 (EAAT1) is a plasma-membrane glutamate transporter belonging to the SLC1 family of solute carriers . It plays a key role in neurotransmitter transport and contributes to the regulation of the extracellular glutamate concentration in the mammalian brain. The structure of EAAT1 was determined in complex with UCPH-101, a highly potent and non-competitive inhibitor of EAAT1. Alanine Serine Cysteine Transporter 2 (ASCT2) is a neutral amino acid transporter, which regulates pools of amino acids such as glutamine, serine and alanine between intracellular and extracellular compartments in a Na+ dependent manner. ASCT2 also belongs to the SLC1 family and shares 58% sequence similarity with EAAT1. However, allosteric modulation of ASCT2 via non-competitive inhibitors is unknown. Here we explore the UCPH-101 inhibitory mechanisms of EAAT1 and ASCT2 by using rapid kinetic experiments. Our results show that UCPH-101 slows substrate translocation rather than substrate or Na+ binding, confirming a non-competitive inhibitory mechanism, but only partially inhibits wild-type ASCT2 with relatively low affinity. Guided by computational modeling using ligand docking and molecular dynamics (MD) simulations, we selected two residues involved in UCPH-101/EAAT1 interaction, which were mutated in ASCT2 (F136Y, I237M, F136Y/I237M) in the corresponding positions. We show that in the F136Y/I237M double mutant transporter, 100% of the inhibitory effect of UCPH-101 on anion current could be restored, and the apparent affinity was increased (Ki = 9.3 mM), much closer to the EAAT1 value of 0.6 mM. Finally, we identify a novel non-competitive ASCT2 inhibitor, identified through virtual screening and experimental testing against the allosteric site, further supporting its localization. Together, these data indicate that the mechanism of allosteric modulation is conserved between EAAT1 and ASCT2. Due to the difference in binding site residues between ASCT2 and EAAT1, these results raise the possibility that more potent, and potentially selective inhibitors can be designed that target the ASCT2 allosteric binding site.

Data availability

All data generated or analyzed during this study are included in the manuscript and supporting file. The original, source data files were uploaded as spreadsheets for figures 3-10, Table 1, and Figure supplements 3,4,5,6 and 9. The MD parametrization files for UCPH-101 are also included.

Article and author information

Author details

  1. Yang Dong

    Department of Chemistry, Binghamton University, Binghamton, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Jiali Wang

    Department of Chemistry, Binghamton University, Binghamton, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9520-8140
  3. Rachel-Ann Garibsingh

    Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, Ney York, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Keino Hutchinson

    Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Yueyue Shi

    Department of Chemistry, Binghamton University, Binghamton, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Gilad Eisenberg

    Department of Chemistry, Binghamton University, Binghamton, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Xiaozhen Yu

    Department of Chemistry, Binghamton University, Binghamton, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Avner Schlessinger

    Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, United States
    For correspondence
    avner.schlessinger@mssm.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4007-7814
  9. Christof Grewer

    Department of Chemistry, Binghamton University, Binghamton, United States
    For correspondence
    cgrewer@binghamton.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8342-9878

Funding

National Institutes of Health (R01 GM108911)

  • Avner Schlessinger
  • Christof Grewer

National Institutes of Health (T32 CA078207)

  • Rachel-Ann Garibsingh

National Institutes of Health (R15 GM135843-01)

  • Christof Grewer

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2023, Dong et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,359
    views
  • 241
    downloads
  • 10
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Yang Dong
  2. Jiali Wang
  3. Rachel-Ann Garibsingh
  4. Keino Hutchinson
  5. Yueyue Shi
  6. Gilad Eisenberg
  7. Xiaozhen Yu
  8. Avner Schlessinger
  9. Christof Grewer
(2023)
Conserved allosteric inhibition mechanism in SLC1 transporters
eLife 12:e83464.
https://doi.org/10.7554/eLife.83464

Share this article

https://doi.org/10.7554/eLife.83464

Further reading

    1. Neuroscience
    2. Structural Biology and Molecular Biophysics
    Yangyu Wu, Yangyang Yan ... Fred J Sigworth
    Research Article

    We present near-atomic-resolution cryoEM structures of the mammalian voltage-gated potassium channel Kv1.2 in open, C-type inactivated, toxin-blocked and sodium-bound states at 3.2 Å, 2.5 Å, 3.2 Å, and 2.9 Å. These structures, all obtained at nominally zero membrane potential in detergent micelles, reveal distinct ion-occupancy patterns in the selectivity filter. The first two structures are very similar to those reported in the related Shaker channel and the much-studied Kv1.2–2.1 chimeric channel. On the other hand, two new structures show unexpected patterns of ion occupancy. First, the toxin α-Dendrotoxin, like Charybdotoxin, is seen to attach to the negatively-charged channel outer mouth, and a lysine residue penetrates into the selectivity filter, with the terminal amine coordinated by carbonyls, partially disrupting the outermost ion-binding site. In the remainder of the filter two densities of bound ions are observed, rather than three as observed with other toxin-blocked Kv channels. Second, a structure of Kv1.2 in Na+ solution does not show collapse or destabilization of the selectivity filter, but instead shows an intact selectivity filter with ion density in each binding site. We also attempted to image the C-type inactivated Kv1.2 W366F channel in Na+ solution, but the protein conformation was seen to be highly variable and only a low-resolution structure could be obtained. These findings present new insights into the stability of the selectivity filter and the mechanism of toxin block of this intensively studied, voltage-gated potassium channel.

    1. Structural Biology and Molecular Biophysics
    Joseph Clayton, Aarion Romany ... Jana Shen
    Research Article

    Aberrant signaling of BRAFV600E is a major cancer driver. Current FDA-approved RAF inhibitors selectively inhibit the monomeric BRAFV600E and suffer from tumor resistance. Recently, dimer-selective and equipotent RAF inhibitors have been developed; however, the mechanism of dimer selectivity is poorly understood. Here, we report extensive molecular dynamics (MD) simulations of the monomeric and dimeric BRAFV600E in the apo form or in complex with one or two dimer-selective (PHI1) or equipotent (LY3009120) inhibitor(s). The simulations uncovered the unprecedented details of the remarkable allostery in BRAFV600E dimerization and inhibitor binding. Specifically, dimerization retrains and shifts the αC helix inward and increases the flexibility of the DFG motif; dimer compatibility is due to the promotion of the αC-in conformation, which is stabilized by a hydrogen bond formation between the inhibitor and the αC Glu501. A more stable hydrogen bond further restrains and shifts the αC helix inward, which incurs a larger entropic penalty that disfavors monomer binding. This mechanism led us to propose an empirical way based on the co-crystal structure to assess the dimer selectivity of a BRAFV600E inhibitor. Simulations also revealed that the positive cooperativity of PHI1 is due to its ability to preorganize the αC and DFG conformation in the opposite protomer, priming it for binding the second inhibitor. The atomically detailed view of the interplay between BRAF dimerization and inhibitor allostery as well as cooperativity has implications for understanding kinase signaling and contributes to the design of protomer selective RAF inhibitors.